1. Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. Effectiveness of botulinum toxin treatment for upper limb spasticity after stroke over different ICF domains: A systematic review and meta-analysis. Arch Phys Med Rehabil 2019; 100: 1703-1725.
2.
Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. Neuro Rehabilitation 2008; 23: 231-237.
3.
Bakheit AMO, Maynard VA, Curnow J, Hudson N, Kodapala S. The relation between Ashworth scale scores and the excitability of the a motor neurones in patients with post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 2003; 74: 646-648.
4.
Baricich A, Picelli A, Molteni F, Guanziroli E, Santamato A. Post-stroke spasticity as a condition: a new perspective on patient evaluation. Funct Neurol 2016; 31: 179-180.
5.
Burke D. Clinical uses of H reflexes of upper and lower limb muscles. Clin Neurophysiol Pract 2016; 1: 9-17.
6.
Cecen S, Niazi IK, Nedergaard RW, Cade A, Allen K, Holt K, Haavik H, Türker KS. Posture modulates the sensitivity of the H-reflex. Exp Brain Res 2018; 236: 829-835.
7.
Chan L, Lin YD, Liu CH. World stroke day in Taiwan: raising public awareness of stroke. Int J Gerontol 2016; 10: 175-179.
8.
Chen YT, Zhang C, Liu Y, Magat E, Verduzco-Gutierrez M, Francisco GE, Zhou P, Zhang Y, Li S. The effects of botulinum toxin injections on spasticity and motor performance in chronic stroke with spastic hemiplegia. Toxins (Basel) 2020; 12: 492.
9.
Ciesla N, Dinglas V, Fan E, Kho M, Kuramoto J, Needham D. Manual muscle testing: a method of measuring extremity muscle strength applied to critically ill patients. J Vis Exp 2011; 50: 2632.
10.
Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity. Medicine 2016; 95: e2468.
11.
Deitz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity: evidence that altered mechanical properties of muscles contribute to hypertonia. Brain 1981; 104: 431-449.
12.
Delwaide PJ. Electrophysiological testing of spastic patients: its potential usefulness and limitations. In: Delwaide PJ, Young RR (Eds.). Clinical neurophysiology of spasticity. Contribution to assessment and pathophysiology. Elsevier, Amsterdam 1985; 185-203.
13.
Dengler R, Kossev A, Wohlfahrt K, Schubert M, Elek J, Wolf W. F waves and motor unit size. Muscle Nerve 1992; 15: 1138-1142.
14.
Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med 2017; 53: 256-267.
15.
El-Tamawy MS, Abdel-Kader A, Fathi S, Samir H, Noha A, El-Bahrawy MN, Darwish M. The role of botulinum toxin (type A) in the management of spastic stroke patients. Egypt J Neurol Psychiat Neurosurg 2004; 41 (suppl. 3): 903-911.
16.
Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113: 400-404.
17.
Ghotbi N, Olyaei GR, Hadian MR, Ansari NN, Bagheri H. Is there any relationship between the Modified Ashworth Scale scores and alpha motoneuron excitability indicators? Electromyogr Clin Neurophysiol 2006; 46: 279-284.
18.
Ghroubi S, Alila S, Elleuch W, Ayed HB, Mhiri C, Elleuch MH. Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity. Pan Afr Med J 2020; 35: 55.
19.
Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology 2017; 89: 2245-2253.
20.
Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve 2005; 31: 535-551.
21.
Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle overactivity. Muscle Nerve 2005; 31: 552-571.
22.
Hiersemenzel LP, Curt A, Dietz V. From spinal shock to spasticity. Neuronal adaptations to spinal cord injury. Neurology 2000; 54: 1574-1582.
23.
Huang CY, Wang CH, Hwang IS. Characterization of the mechanical and neural components of spastic hypertonia with modified H reflex. J Electromyogr Kinesiol 2006; 16: 384-391.
24.
Jaberzadeh S, Scutter S, Warden-Flood A, Nazeran H. Between-days reliability of H-reflexes in human flexor carpi radialis. Arch Phys Med Rehabil 2004; 85: 1168-1173.
25.
Jankovic J. Botulinum toxin: State of the art. Mov Disord 2017; 32: 1131-1138.
26.
Joodaki MR, Olyaei GR, Bagheri H. The effects of electrical stimulation of the lower extremity on H-reflex and F-wave parameters. Electromyogr Clin Neurophysiol 2001; 41: 21-28.
27.
Kerzoncuf M, Bensoussan L, Delarque A, Durand J, Viton JM, Rossi-Durand C. Plastic changes in spinal synaptic transmission following botulinum toxin A in patients with post-stroke spasticity. J Rehabil Med 2015; 47: 910-916.
28.
Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012; 12: 289-298.
29.
Knikou M. The H-reflex as a probe: Pathways and pitfalls. J Neurosci Methods 2008; 171: 1-12.
30.
Kuo CL, Hu GC. Post-stroke spasticity: A review of epidemiology, pathophysiology, and treatments. Int J Gerontol 2018; 12: 280-284.
31.
Li S. Spasticity, motor recovery, and neural plasticity after stroke. Front Neurol 2017; 8: 120.
32.
López de Munain L, Valls-Solé J, Garcia Pascual I, Maisonobe P; on behalf of the VALGAS investigators group. Botulinum Toxin type A improves function according to goal attainment in adults with poststroke lower limb spasticity in real life practice. Eur Neurol 2019; 82: 1-8.
33.
Lundström E, Smits A, Terént A, Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med 2010; 42: 296-301.
34.
Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am 2003; 14: 855-883.
35.
Milanov GI. A comparison of methods to assess the excitability of lower motorneurones. Can J Neurol Sci 1992; 19: 64-68.
36.
Naghdi S, Ansari NN, Mansouri K, Asgari A, Olyaei GR, Kazemnejad A. Neurophysiological examination of the Modified Modified Ashworth Scale (MMAS) in patients with wrist flexor spasticity after stroke. Electromyogr Clin Neurophysiol 2008; 48: 35-41.
37.
Nam KE, Lim SH, Kim JS, Hong BY, Jung HY, Lee JK, Yoo SD, Pyun SB, Lee KM, Lee KJ, Kim H, Han EY, Lee KW. When does spasticity in the upper limb develop after a first stroke? A nationwide observational study on 861 stroke patients. J Clin Neurosci 2019; 66: 144-148.
38.
O’Dwyer N, Ada L, Neilson P. Spasticity and muscle contracture following stroke. Brain 1996; 119: 1737-1749.
39.
Opheim A, Danielsson A, Alt Murphy M, Persson HC, Sunnerhagen KS. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil 2014; 93: 884-896.
40.
Pensini M, Martin A. Effect of voluntary contraction intensity on the H-reflex and V-wave response. Neurosci Lett 2004; 367: 369-374.
41.
Phadke CP, Robertson CT, Condliffe EG, Patten C. Upper-extremity H-reflex measurement post-stroke: Reliability and inter-limb differences. Clin Neurophysiol 2012; 123: 1606-1615.
42.
Picelli A, Santamato A, Cosma M, Baricich A, Chisari C, Millevolte M, Prete CD, Mazzù I, Girardi P, Smania N. Early botulinum toxin type A injection for post-stroke spasticity: A longitudinal cohort study. Toxins (Basel) 2021; 13: 374.
43.
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol Rev 2017; 9: 200-235.
44.
Sarzyńska-Długosz I, Szczepańska-Szerej A, Drużdż A, Łukomski T, Ochudło S, Fabian A, Sobolewski P, Mariańska K, Maciejewska J, Mulek E, Niedzielska A, Raymond R, Brzózka MM, Jessa-Jabłońska M. Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study. Neurol Neurochir Pol 2020; 54: 90-99.
45.
Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44: 167-193.
46.
Stokic DS, Yablon SA, Hayes A, Vesovic-Potic V, Olivier J. Dose-response relationship between the H-reflex and continuous intrathecal baclofen administration for management of spasticity. Clin Neurophysiol 2006; 117: 1283-1289.
47.
Sugawara K, Kasai T. Facilitation of motor evoked potentials and H-reflexs of flexor carpi radialis muscle induced by voluntary teeth clenching. Hum Mov Sci 2002; 21: 203-212.
48.
Thibaut A, Chatelle C, Ziegler E, Bruno MA, Laureys S, Gosseries O. Spasticity after stroke: physiology, assessment and treatment. Brain Inj 2013; 27: 1093-1105.
49.
Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, Bauermann T, Weibrich C, Vucurevic GD, Schneider A, Wissel J. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41: 2016-2020.
50.
Vattanasilp W, Ada L, Crosbie J. Contribution of thixotropy, spasticity, and contracture to ankle stiffness after stroke. J Neurol Neurosurg Psychiatry 2000; 69: 34-39.
51.
Wemove Worldwide Education and Awareness for Movement Disorders, 2001. https://www.movementdisorders.org/MDS/About.htm?gclid=Cj0KCQiApKagBhC1ARIsAFc7Mc7QE7lQLNp5QL8Ersnie85tRqV3Dytd7USSh2XWojMtB9aBCfZKTZ0aAtm-EALw_wcB
52.
Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010; 257: 1067-1072.
53.
Zeng H, Chen J, Guo Y, Tan S. Prevalence and risk factors for spasticity after stroke: A systematic review and meta-analysis. Front Neurol 2020; 11: 616097.
